RGLS 5040Alternative Names: RGLS-5040
Latest Information Update: 13 Dec 2016
At a glance
- Originator Regulus Therapeutics
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cholestasis